tirzepatide patent expiry in india Looming GLP-1 drug expirations draw generics firms Weight-Loss Drugs Set To Get

In 2021, the FDA approved a third semaglutide formulation, Wegovy, for chronic weight management for those with obesity or overweight and at least one weight-related condition

Whichever route is chosen, there is a defined legal process that must be followed

While many of the key regulators of this pathway remain largely unknown, recent studies have identified glutathione peroxidases, particularly glutathione peroxidase 4 (GPX4), as antioxidant enzymes that can prevent lipid peroxidation using reduced glutathione (GSH) as a co-factor 9,10

The choice of medication should be based on discussions and individualized guidance from a healthcare professional who has a comprehensive understanding of your medical condition

Neither substitutes for the other

While results vary, the benefits below reflect how GLP-1based treatments are generally experienced when used consistently